Phreesia, Inc. (PHR) Dividend History

Company News

• A Glimpse Into The Expert Outlook On Phreesia Through 6 Analysts

  Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Phreesia (NYSE:PHR) in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.83, a high estimate of $34.00, and a low estimate of $28.00. A decline of 4.79% from the prior average price target is evident in the current average. Decoding Analyst Ratings: A Detailed Look In examining recent analyst actions, we gain insights into how financial experts perceive Phreesia. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jailendra Singh Truist Securities Maintains Buy $29.00 $29.00 Jailendra Singh Truist Securities Lowers Buy $29.00 $35.00 Richard Close Canaccord Genuity Lowers Buy $34.00 $37.00 Jeff Garro Stephens & Co. Maintains Overweight $28.00 $28.00 Joe Goodwin JMP Securities Maintains Market Outperform $30.00 $30.00 Ryan MacDonald Needham Maintains Buy $29.00 $29.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Phreesia. This information provides a snapshot of how analysts perceive the current state of the company. Rating: ...Full story available on Benzinga.com

  Benzinga
• Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

  Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include CLEAR Secure (YOU), Applied DNA Sciences (APDN), Phreesia (PHR), Vigil Neuroscience (VIGL) and Biodesix (BDSX).

  Zacks Investment Research

  Featured Companies: APDN BDSX VIGL YOU
• 5 Medical Info Systems Stock to Buy for a Stable Portfolio

  We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

  Zacks Investment Research

  Featured Companies: ENOV HIMS LAB LUNG
• Here's Why Phreesia (PHR) is Poised for a Turnaround After Losing -18.25% in 4 Weeks

  Phreesia (PHR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

  Zacks Investment Research
• Assessing Phreesia: Insights From 12 Financial Analysts

  Across the recent three months, 12 analysts have shared their insights on Phreesia (NYSE:PHR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 6 3 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 6 3 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.0, a high estimate of $37.00, and a low estimate of $23.00. Observing a 3.06% increase, the current average has risen from the previous average price target of $28.14. Diving into Analyst Ratings: An In-Depth Exploration An in-depth analysis of recent analyst actions unveils how financial experts perceive Phreesia. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Ryan MacDonald Needham Maintains Buy $29.00 $29.00 Jeff Garro Stephens & Co. Maintains Overweight $28.00 - Sean Dodge RBC Capital Maintains Sector Perform $23.00 - Joe Goodwin JMP Securities Raises Market Outperform $30.00 $28.00 Joseph Vruwink Baird Raises Outperform $31.00 $30.00 Ryan MacDonald Needham Maintains Buy $29.00 - Sean Dodge RBC Capital Raises Sector Perform $23.00 $17.00 John Ransom Raymond James Raises Outperform $30.00 $25.00 Joe Goodwin JMP Securities Maintains Market Outperform $28.00 - Robert Simmons DA Davidson Maintains Neutral $32.00 $32.00 Richard Close Canaccord Genuity Raises Buy $37.00 $36.00 Joe Goodwin JMP Securities Maintains Market Outperform $28.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', ...Full story available on Benzinga.com

  Benzinga